About Freeline
Freeline is a company based in Stevenage (United Kingdom) founded in 2015 was acquired by Syncona in November 2023.. Freeline has raised $273.69 million across 6 funding rounds from investors including Syncona, TD Securities and UCL Technology Fund. The company has 152 employees as of December 31, 2020. Freeline has completed 1 acquisition, including SwanBio Therapeutics. Freeline offers products and services including FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN. Freeline operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Stevenage, United Kingdom
- Employees 152 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Freeline Therapeutics Limited
- Date of Incorporation 19 Mar, 2015
- Jurisdiction STEVENAGE, HERTFORDSHIRE, ENGLAND
-
Annual Revenue
$435.87 K (USD)0as on Dec 31, 2018
-
Net Profit
$-38.39 M (USD)-88as on Dec 31, 2018
-
EBITDA
-
Total Equity Funding
$273.69 M (USD)
in 6 rounds
-
Latest Funding Round
$125.51 M (USD), Post-IPO
Aug 14, 2020
-
Investors
Syncona
& 7 more
-
Employee Count
152
as on Dec 31, 2020
- Investments & Acquisitions
-
Acquired by
Syncona
(Nov 22, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Freeline
Freeline offers a comprehensive portfolio of products and services, including FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Gene therapy candidate targeting Gaucher Disease through clinical trials.
Treatment aimed at modifying Parkinson's Disease progression.
First-in-class therapy for adrenomyeloneuropathy conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Freeline
Freeline has successfully raised a total of $273.69M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125.51 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $125.5M
-
First Round
First Round
(01 Dec 2015)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Post-IPO - Freeline | Valuation |
investors |
|
| Jun, 2020 | Amount | Series C - Freeline | Valuation | Novo Holdings , Eventide Funds | |
| Dec, 2019 | Amount | Series C - Freeline | Valuation | Syncona |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Freeline
Freeline has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, TD Securities and UCL Technology Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Healthcare investments are managed via private equity by Syncona.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Freeline
Freeline has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SwanBio Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AAV-based gene therapy for neurological diseases is provided.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Freeline
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Freeline Comparisons
Competitors of Freeline
Freeline operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Freeline
Frequently Asked Questions about Freeline
When was Freeline founded?
Freeline was founded in 2015.
Where is Freeline located?
Freeline is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Who is the current CEO of Freeline?
Michael Parini is the current CEO of Freeline.
Is Freeline a funded company?
Freeline is a funded company, having raised a total of $273.69M across 6 funding rounds to date. The company's 1st funding round was a Series C of $40M, raised on Dec 01, 2015.
How many employees does Freeline have?
As of Dec 31, 2020, the latest employee count at Freeline is 152.
What is the annual revenue of Freeline?
Annual revenue of Freeline is $435.87K as on Dec 31, 2018.
What does Freeline do?
Freeline was founded in 2015 in Stevenage, United Kingdom, as a biotechnology company focused on gene therapy. A platform is offered to deliver therapeutic genes to the liver, enabling secretion of proteins for patients with hemophilia (FLT180a) and Fabry disease (FLT190). Lysosomal storage disorders are diagnosed, and clinical trial solutions are provided to support hemophilia management procedures.
Who are the top competitors of Freeline?
Freeline's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Freeline offer?
Freeline offers FLT201, Gene Therapy for Parkinson's, and Gene Therapy for AMN.
How many acquisitions has Freeline made?
Freeline has made 1 acquisition, including SwanBio Therapeutics.
Who are Freeline's investors?
Freeline has 8 investors. Key investors include Syncona, TD Securities, UCL Technology Fund, Novo Holdings, and Eventide Mutual Funds.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.